A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity

NCT07724340 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Adults With Overweight/Obesity and Type 2 Diabetes

Interventions

DRUG: AT673 low dose
DRUG: AT673 high dose
DRUG: Placebo

Sponsor

Antag Therapeutics